Anvisa has granted Eurofarma the first generic registration for the dapagliflozin-metformin fixed-dose combination, mandating a minimum 35% price discount versus AstraZeneca’s Xigduo XR under Generic Law 9.787/1999.
Anvisa has granted Eurofarma the first generic registration for the dapagliflozin-metformin fixed-dose combination, mandating a minimum 35% price discount versus AstraZeneca’s Xigduo XR under Generic Law 9.787/1999.
ANS has added a PARP inhibitor for BRCA1/2-positive metastatic castration-resistant prostate cancer to Brazil’s mandatory private insurance coverage list, effective July 1, 2026, following public consultation.
ANS mandates private-plan coverage for olaparib in BRCA-mutant prostate cancer, osimertinib plus chemotherapy in EGFR+ lung cancer, and lebriquizumab in severe atopic dermatitis following a price concession.
You must be logged in to post a comment.